Objective: The article examines the objective, findings, and clinical context described in FDA approves first NPC survival treatment. Approach: Approval populat
The FDA approved adrabetadex (Lembaz) as the first treatment shown to reduce mortality risk in Niemann-Pick disease type C.
Approval covers adults and children weighing at least 7 kg whose neurological symptoms began before age 6.
In a nonrandomized analysis, median overall survival was 102 months with adrabetadex and 59 months in matched external controls, with a 55% lower relative risk of death.
Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss, and requires audiological evaluations before treatment and during dose escalation.
Adrabetadex is administered intrathecally every 2 weeks by or under the supervision of a clinician experienced in lumbar punctures.
Objective: The article summarizes four reports: a case of a swallowed spoon requiring surgery, a mouse study of dietary cellulose and nanoplastic exposure, a re
Surgeons removed an 18-cm spoon lodged in a 28-year-old man’s duodenum for nearly 3 months; he later required surgery for adhesive small bowel obstruction.
In male mice, a 50% cellulose diet was associated with greater nanoplastic excretion and less intestinal accumulation than diets containing 5% or 15% cellulose.
A review of 10 studies involving 365 adults found that odors sometimes affected postural control, but evidence certainty ranged from moderate to very low.
In a 13-year cohort study of 1,708 adults, moderate tea consumption was generally associated with more favorable bone measurements, but the study could not establish causation.
The nanoplastic findings came from male mice fed fiber concentrations exceeding typical human diets, and the researchers said human studies are needed.
Objective: The article examines the objective, findings, and clinical context described in Making Pediatric Leukemia Testing Accessible. Approach: Current testi
Objective: The article describes point-of-care (POC) testing for sexually transmitted infections, including available assays, potential benefits, and the role o
Point-of-care STI tests provide results near the site of care, typically within minutes to an hour, enabling clinical decisions during the same visit.
FDA-cleared, CLIA-waived molecular assays can detect chlamydia and gonorrhea in about 20 minutes, with accuracy approaching laboratory-based testing.
Same-visit results can reduce dependence on follow-up, which is especially important for people facing barriers to care or at increased risk of being lost to follow-up.
Point-of-care testing may reduce empiric treatment and unnecessary antibiotic exposure, while supporting antimicrobial stewardship.
Implementation challenges include cost, operational complexity, specimen-type restrictions, workflow demands, and the need for staff training and quality oversight.
Objective: To assess whether postoperative suction drains are associated with blood loss, transfusion, length of stay, or complications after primary total hip
Objective: The article examines the objective, findings, and clinical context described in FDA approves neladalkib for ALK-positive lung cancer. Approach: Appro
The FDA granted accelerated approval to neladalkib for adults with locally advanced or metastatic ALK-positive NSCLC after specified prior targeted therapy.
Eligible patients had received alectinib as their only prior ALK TKI in the advanced setting or at least 2 ALK TKIs and platinum-based chemotherapy.
In ALKOVE-1, the confirmed overall response rate was 49% among 67 patients previously treated only with alectinib and 32% among 155 patients in the other treatment group.
Among responders, 76% and 52% in the alectinib-only group maintained responses for at least 6 and 12 months, respectively; corresponding rates in the other group were 69% and 51%.
Neladalkib is taken orally at 150 mg once daily; warnings include hepatotoxicity, renal and ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity.
Objective: The article examines the objective, findings, and clinical context described in A Faster Route to Antibody Peptide Maps. Approach: Workflow: The meth
Objective: To assess whether an AI model can detect pancreatic cancer-associated changes in CT scans before the disease is clinically diagnosed. Approach: Model
The Mayo Clinic-developed REDMOD analyzed subtle pancreatic tissue changes in CT scans that were not visible to experienced radiologists.
The study evaluated 1,462 CT scans, including 219 from patients who later developed pancreatic cancer and 1,243 from individuals without the disease.
In independent testing, REDMOD detected 73% of patients who later developed cancer, compared with 39% detected by radiologists; the median interval to diagnosis was 475 days.
REDMOD maintained 68% sensitivity in scans obtained more than 2 years before diagnosis, while external validation showed specificity ranging from 81% to 88%.
The retrospective study did not establish whether earlier detection improves survival, and prospective validation is needed; the model also incorrectly flagged about 1 in 5 cancer-free individuals.
Objective: To evaluate the efficacy and safety of mivocabtagene autoleucel in adults with antibody-positive stiff person syndrome (SPS) who had responded inadeq
Agentic AI can retrieve information, coordinate tasks, assemble evidence, and flag risks while people retain responsibility for scientific decisions.
In clinical development, agents can combine historical recruitment, eligibility, and site-capability data to prepare feasibility assessments for expert review.
Agents can monitor study startup and execution, identify missing operational inputs, track recruitment and protocol adherence, and escalate emerging risks.
In pharmacovigilance and regulatory work, agents can assemble case information and submission materials, draft content, and flag missing data or inconsistencies.
Effective use depends on well-designed workflows, connected data, human review, and governance that documents agent outputs, evidence, risks, and human decisions.
Objective: Develop a human stem cell-derived model that reproduces key features of lens development for research into lens biology and disease. Approach: Organo
Researchers used SEAM differentiation and lens-optimized medium to generate human induced pluripotent stem cell-derived lens organoids, or lentoids, over 8 weeks.
Compared with conventional ocular differentiation medium, optimized cultures produced larger and more numerous lentoids with increased expression of lens-associated genes.
Expression of CRYGA and CRYGB increased approximately 63-fold and 59-fold, respectively, while connexins CX46 and CX50 and N-cadherin also increased.
Electron microscopy showed elongated fibre-like cells, epithelial layers, capsule-like structures, and intercellular junctions resembling features of the human lens.
Isolated lentoids generated proliferating lens epithelial-like cells that expressed PAX6, SIX3, and SOX2 and later formed secondary lentoids; optical testing and further maturation assessments remain
Objective: Develop a human stem cell-derived model that reproduces key features of lens development for research into lens biology and disease. Approach: Organo
Researchers used SEAM differentiation and lens-optimized medium to generate human induced pluripotent stem cell-derived lens organoids, or lentoids, over 8 weeks.
Compared with conventional ocular differentiation medium, optimized cultures produced larger and more numerous lentoids with increased expression of lens-associated genes.
Expression of CRYGA and CRYGB increased approximately 63-fold and 59-fold, respectively, while connexins CX46 and CX50 and N-cadherin also increased.
Electron microscopy showed elongated fibre-like cells, epithelial layers, capsule-like structures, and intercellular junctions resembling features of the human lens.
Isolated lentoids generated proliferating lens epithelial-like cells that expressed PAX6, SIX3, and SOX2 and later formed secondary lentoids; optical testing and further maturation assessments remain
Objective: To describe and compare the demographic, geographic, and state-level correlates of the 1985–1993 and 2014–2021 US firearm homicide surges. Approach:
Using national mortality data from 1979 to 2023, Morral and Smart compared the demographic and geographic patterns and state-level correlates of firearm homicide surges in 1985-1993 and 2014-2021.
The 2014-2021 surge was larger and more broadly distributed than the 1985-1993 surge, with more deaths in rural settings and among females, older people, and people of races other than Black.
The earlier surge was more concentrated among young Black males in urban areas, while each surge had distinct state-level correlates.
Both surges were associated with structural vulnerability, including higher unemployment, poverty, household instability, and premature mortality.
The authors describe their findings as descriptive and call for further research to characterize the post-2021 decline and clarify its causes.
Objective: The article examines the objective, findings, and clinical context described in FDA approves giredestrant for breast cancer. Approach: Approval: The
The FDA approved giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after specified prior endocrine therapy.
The FDA authorized FoundationOne Liquid CDx as a companion diagnostic to identify patients with ESR1 mutations.
In the phase 3 evERA trial, median progression-free survival among patients with ESR1-mutated tumors was 10 months with giredestrant plus everolimus and 5.5 months with comparator endocrine therapy pl
Objective response rates in patients with ESR1-mutated tumors were 27% with giredestrant plus everolimus and 14% with comparator endocrine therapy plus everolimus; overall survival data were immature.
Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea; the prescribing information warns of bradycardia and embryo-fetal toxicity.
Objective: The article examines the objective, findings, and clinical context described in First IL-17A biologic approved for polymyalgia rheumatica. Approach:
The FDA approved secukinumab 150 mg as the first IL-17A inhibitor for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering.
In the 381-participant REPLENISH trial, sustained remission at week 52 occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab and 2,093 mg with placebo.
Median time to rescue treatment for a polymyalgia rheumatica flare was 282 days with secukinumab and 157 days with placebo.
The prescribing information warns of serious infections and inflammatory bowel disease and recommends tuberculosis evaluation and age-appropriate vaccinations before treatment.